Cargando…

Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia

Minimal residual disease (MRD) refers to a chemotherapy/radiotherapy-surviving leukemia cell population that gives rise to relapse of the disease. The detection of MRD is critical for predicting the outcome and for selecting the intensity of further treatment strategies. The development of various n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kruse, Aaron, Abdel-Azim, Nour, Kim, Hye Na, Ruan, Yongsheng, Phan, Valerie, Ogana, Heather, Wang, William, Lee, Rachel, Gang, Eun Ji, Khazal, Sajad, Kim, Yong-Mi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037356/ https://www.ncbi.nlm.nih.gov/pubmed/32033444 http://dx.doi.org/10.3390/ijms21031054

Ejemplares similares

Characterizing the Motility of Chemotherapeutics-Treated Acute Lymphoblastic Leukemia Cells by Time-Lapse Imaging
por: Liu, Hsiao-Chuan, et al.
Publicado: (2020)

Cadherins, Selectins, and Integrins in CAM-DR in Leukemia
por: Kim, Hye Na, et al.
Publicado: (2020)

Wnt Signaling in Leukemia and Its Bone Marrow Microenvironment
por: Ruan, Yongsheng, et al.
Publicado: (2020)

Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia
por: Ruan, Yongsheng, et al.
Publicado: (2021)

In vitro and in vivo effects of AVA4746, a novel competitive antagonist of the ligand binding of VLA-4, in B-cell acute lymphoblastic leukemia
por: Ruan, Yongsheng, et al.
Publicado: (2022)

Artemis inhibition as a therapeutic strategy for acute lymphoblastic leukemia
por: Ogana, Heather A., et al.
Publicado: (2023)

Minimal residual disease in acute lymphoblastic leukemia: technical aspects and implications for clinical interpretation
por: Kim, In-Suk
Publicado: (2020)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
por: Della Starza, Irene, et al.
Publicado: (2019)

Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia: Egyptian Experience
por: Ibrahim, Rasha Ibrahim, et al.
Publicado: (2022)

Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey
por: Pigneux, Arnaud, et al.
Publicado: (2018)

Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia
por: Rocha, Juliana Maria Camargos, et al.
Publicado: (2016)

Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia
por: Latham, Sue, et al.
Publicado: (2017)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions
por: Contreras Yametti, Gloria Paz, et al.
Publicado: (2021)

Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia
por: Della Starza, Irene, et al.
Publicado: (2023)

Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
por: Gibson, Amber, et al.
Publicado: (2021)

Characterizing Deformability of Drug Resistant Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells Using Acoustic Tweezers
por: Liu, Hsiao-Chuan, et al.
Publicado: (2018)

The utility of multiparametric flow cytometry for the detection of minimal residual disease in acute lymphoblastic leukemia
por: Cunha, Fernanda Gonçalves Pereira, et al.
Publicado: (2012)

Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia
por: Rzepiel, Andrea, et al.
Publicado: (2019)

The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia
por: Ragoonanan, Dristhi, et al.
Publicado: (2022)

P366: ARE MINIMAL RESIDUAL DISEASE MEASUREMENTS AFTER CONSOLIDATION THERAPY USEFUL IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA?
por: Stutterheim, Janine, et al.
Publicado: (2023)

Clinical implication of minimal residual disease assessment by next-generation sequencing-based immunoglobulin clonality assay in pediatric B-acute lymphoblastic leukemia
por: Lee, Jae Wook, et al.
Publicado: (2022)

Transcriptome Analysis of Minimal Residual Disease in Subtypes of Pediatric B Cell Acute Lymphoblastic Leukemia
por: Sitthi-amorn, Jitsuda, et al.
Publicado: (2015)

Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
por: Ikoma, Maura Rosane Valério, et al.
Publicado: (2015)

Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia
por: O’Connor, David, et al.
Publicado: (2018)

Minimal residual disease in childhood B Lymphoblastic Leukemia and its correlation with other risk factors
por: Meraj, Fatima, et al.
Publicado: (2020)

Targeting PI3K Signaling in Acute Lymphoblastic Leukemia
por: Sanchez, Vanessa Edna, et al.
Publicado: (2019)

Cardiac Relapse of Acute Lymphoblastic Leukemia Following Hematopoietic Stem Cell Transplantation: A Case Report and Review of Literature
por: Sheikh, Irtiza N., et al.
Publicado: (2021)

Minimal residual disease detection in Tunisian B-acute lymphoblastic leukemia based on immunoglobulin gene rearrangements
por: Besbes, S., et al.
Publicado: (2017)

Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia
por: Galimberti, Stefania, et al.
Publicado: (2018)

TFDP3 confers chemoresistance in minimal residual disease within childhood T-cell acute lymphoblastic leukemia
por: Chu, Ming, et al.
Publicado: (2016)

Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia
por: Jovanovska, Aleksandra, et al.
Publicado: (2019)

Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia
por: Shin, Saeam, et al.
Publicado: (2017)

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913
por: Chiaretti, Sabina, et al.
Publicado: (2020)

Phosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic Leukemia
por: George, Aswathi A., et al.
Publicado: (2015)

Translational advances in the treatment of childhood acute lymphoblastic leukemia: narrative review of current and emerging molecular and immunotherapies
por: Munir, Faryal, et al.
Publicado: (2023)

Prognostic Significance and Treatment Implications of Minimal Residual Disease Studies in Philadelphia-Negative Adult Acute Lymphoblastic Leukemia
por: Spinelli, Orietta, et al.
Publicado: (2014)

Clinicians’ Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study
por: Gidman, Wendy, et al.
Publicado: (2019)

Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy
por: Tambaro, Francesco Paolo, et al.
Publicado: (2020)

Eosinophilic presentation of acute lymphoblastic leukemia
por: Rezamand, Azim, et al.
Publicado: (2013)

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia
por: Pulsipher, Michael A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rhbb9khbt3eg0okuot8ebalfst